Low-grade Adenosquamous Carcinoma Research Articles

Cytologic analysis of metaplastic breast carcinoma: Review of 66 cases diagnosed at the Institut Curie.

Cytology reports of metaplastic breast carcinoma (MBC) are rare and limited to short series and simple case reports. To adapt cytology diagnostic criteria to the most recent fifth edition of the World Health Organization Classification of Breast Tumours from 2019, we have reviewed our series from the files of the Institut Curie. A cohort of 66 female patients investigated by cytology with corresponding histologic diagnosis of MBC was identified. Eight cytologic characteristics were analyzed: cellularity, adenocarcinoma cells, squamous cells, spindle cells, giant cells, cytonuclear atypia, necrosis, and osseous/chondroid matrix and compared with histology. Cytologic diagnoses were malignant in 58 (88%) cases (of which 29 cases were typed cytologically as MBC), suspicious in 6 (9%) cases, and nondiagnostic in 2 (3%) cases. None of the cytologic examinations was a benign diagnosis. Low-grade adenosquamous carcinoma and fibromatosis-like metaplastic carcinoma exhibited a low degree of cellular atypia. Fibromatosis-like metaplastic carcinoma and spindle cell carcinoma (SpCC) presented spindle cells, while SpCC also demonstrated varying degrees of atypia, the presence of giant cells, and necrosis. Squamous cell carcinoma was characterized by the presence of squamous cells, and metaplastic carcinoma with osseous/chondroid differentiation displayed an osseous/chondroid matrix. Fine-needle aspiration holds considerable potential as a valid, independent, and complementary approach to histologic examination of MBC.

Genetic analysis of low-grade adenosquamous carcinoma of the breast progressing to high-grade metaplastic carcinoma

PurposeLow-grade adenosquamous carcinoma (LGASC) is a rare type of metaplastic carcinoma of the breast (MBC) with an indolent clinical course. A few LGASC cases with high-grade transformation have been reported; however, the genetics underlying malignant progression of LGASC remain unclear.MethodsWe performed whole-genome sequencing analysis on five MBCs from four patients, including one case with matching primary LGASC and a lymph node metastatic tumor consisting of high-grade MBC with a predominant metaplastic squamous cell carcinoma component (MSC) that progressed from LGASC and three cases of independent de novo MSC.ResultsUnlike de novo MSC, LGASC and its associated MSC showed no TP53 mutation and tended to contain fewer structural variants than de novo MSC. Both LGASC and its associated MSC harbored the common GNAS c.C2530T:p.Arg844Cys mutation, which was more frequently detected in the cancer cell fraction of MSC. MSC associated with LGASC showed additional pathogenic deletions of multiple tumor-suppressor genes, such as KMT2D and BTG1. Copy number analysis revealed potential 18q loss of heterozygosity in both LGASC and associated MSC. The frequency of SMAD4::DCC fusion due to deletions increased with progression to MSC; however, chimeric proteins were not detected. SMAD4 protein expression was already decreased at the LGASC stage due to unknown mechanisms.ConclusionNot only LGASC but also its associated high-grade MBC may be genetically different from de novo high-grade MBC. Progression from LGASC to high-grade MBC may involve the concentration of driver mutations caused by clonal selection and inactivation of tumor-suppressor genes.

The conundrum of metaplastic breast cancer: a single Egyptian institution retrospective 10-year experience (2011–2020)

BackgroundMetaplastic breast cancer (MetBC) still represents a conundrum owing to its peculiar histogenesis and molecular drivers that render it extremely resistant to standard chemotherapy with ultimate dismal survival.AimDescribe the Egyptian National Cancer Institute’s (NCI-E) experience with MetBC regarding its clinicopathologic features, treatment, and survival outcomes.Patients and methodsBetween 2011 and 2020, all MetBC patients presented to NCI-E were retrospectively evaluated. Original clinicopathologic data, therapeutic modalities, pathologic response to neoadjuvant chemotherapy (NACT), recurrence, and date of last follow-up/death were obtained from archived charts.ResultsA cohort of 135 females, the median age was 52 years, and median follow-up period was 40 months (range: 2.6–130.8). Two-thirds were triple negative (TN). Squamous carcinoma was prevalent in 74.8% followed by carcinoma with osseous/chondroid differentiation, spindle cell, and low-grade adenosquamous carcinoma encountered in 13.3, 7.4, and 4.5%, respectively. Modified radical mastectomy was done in 59.3%, and positive nodes (pN+) were depicted in 37.7%. Median Ki-67 was 45% (range: 10–88); grade III and lymphovascular invasion (LVI) were observed in 83.7 and 43.7%, respectively. Stage II was the most common (49%), whereas initial stage IV was encountered in 8.1%. Anthracyclines/taxane combinations were rampant in adjuvant/neoadjuvant settings. The latter was employed in 41 patients, with only 3 cases (7.3%) achieving pathologic complete response (pCR), while moderate/significant residual tumor burden was found in 83%. The 5-year DFS and OS were 56.4 and 57.6%, respectively. Spindle cell carcinoma showed the worst survival parameters in univariate analysis. On the multivariate level, higher tumor stage (pT3 & 4), Ki-67 ≥ 45%, and TN subtype were independent variables for worse DFS and OS; age ≥ 52 years and the presence of LVI were independent features for worse DFS, whereas pN+ was an independent parameter for worse OS.ConclusionsThis study further solidifies the dreadful response of MetBC to conventional chemotherapy regimens employed in common non-metaplastic pathologies. A radical shift in treatment standards tailored to combat the molecular landscape of this distinctive tumor is urgently needed. Immunotherapy and molecularly targeted agents demonstrated promising results in phase I and II trials with hopeful sooner implementation in phase III studies.

Low-grade adenosquamous carcinoma of the breast: aclinical, morphological and immunohistochemical analysisof 25 patients.

Due to its rarity and non-specific clinical and pathological features, low-grade adenosquamous carcinoma (LGASC) of the breast continues to pose diagnostic challenges. Unlike other triple-negative breast carcinomas, LGASC tends to have an indolent clinical behaviour. It is essential to recognise this lesion for accurate diagnosis and appropriate management. Twenty-five cases of LGASC were identified in our archives and collaborating institutes. Cases of LGASC with dominant coexisting other type carcinomas were excluded. We studied the clinical presentation, morphological features, patterns of the commonly used immunohistochemical stains and follow-up. In our cohort, LGASC was commonly located at the outer aspect of the breast and associated with intraductal papilloma. The morphology of LGASC is characterised by infiltrating small glands and nests with variable squamous differentiation. We also found cuffing desmoplastic (fibrolamellar) stromal change in 75% of patients and peripheral lymphocytic aggregates in 87.5% of patients. P63 and smooth muscle myosin (SMM) were the most common myoepithelial markers used to assist in diagnosis. P63 often stained peripheral tumour cells surrounding invasive glands (circumferential staining in 80% of the cases), mimicking myoepithelial cells. It also stained the small nests with squamous differentiation. However, SMM was negative in 63% of the cases. The vast majority of our cases were triple-negative; only a few had focal and weak expressions of ER and PR. One patient who did not have excision developed lymph node metastasis. Most patients underwent excision or mastectomy with negative margins as surgical treatment; there were no recurrences or metastases in these patients with clinical follow-ups up to 108 months. LGASC has some unique, although not entirely specific, morphological features and immunohistochemical staining patterns. Fibrolamellar stromal change, peripheral lymphocytic aggregates and variable staining of p63 and SMM are valuable features to facilitate the diagnosis.

Abstract P1-05-31: A single center retrospective analysis of 259 cases of metaplastic breast cancer

Abstract Introduction: Metaplastic breast cancer (MBC) is a rare breast tumor.WHO histological classification of breast tumors in 2019 divided MBC into the following seven types: low-grade adenosquamous carcinoma, fibromatoid metaplastic carcinoma, squamous cell carcinoma, spindle cell carcinoma, metaplastic carcinoma with mesenchymal differentiation, mixed metaplastic carcinoma and myoepithelial carcinoma. Based on single center data, this study intends to conduct a detailed analysis of the clinicopathological features, treatment and prognostic factors of MBC. Methods:We collected 259 MBCs treated in our center from 2006 to 2022. The patient’s age, histological type, image feature, tumor size, lymph node metastasis, tumor stage, immunohistochemical information, surgical plan and systemic adjuvant therapy were summarized and considered to explore the factors affecting the overall survival rate (OS) and disease-free survival rate (DFS). T-test and chi-square test were performed on the data. P< 0.05 showed that the difference was statistically significant. Kaplan-Meier survival was used to analyze the long-term efficacy. Results: The incidence rate of MBC in breast cancer patients in our center is about 0.5%. They included 105 cases of squamous cell carcinoma (40.5%), 49 cases of mixed metaplastic carcinoma (18.9%), 41 cases of spindle cell carcinoma (15.8%), 27 cases of metaplasia carcinoma secreting matrix (10.4%), 6 cases of metaplastic carcinoma with mesenchymal differentiation (2.3%), 6 cases of myoepithelial carcinoma (2.3%), 3 cases of low-grade adenosquamous carcinoma (1.2%), 1 case of fibromatoid metaplasia carcinoma (0.4%) and 21 cases of unknown (8.1%). MBC were mainly three negative subtypes, which were 204 cases (78.8%), 41 cases (15.8%) luminal subtypes and 14 cases (5.4%) HER2 positive subtypes. There was no significant difference in the distribution of breast cancer subtypes among different histological types of MBC. There were 63 cases (24.3%) in clinical stage I, 171 cases (66.0%) in stage II, 23 cases (8.9%) in stage III and 2 cases (0.8%) in stage IV. 58 patients underwent core needle biopsy, of which only 7 (12.1%) reported histological types consistent with MBC. Among 154 patients with molybdenum target reports, 59 of them (38.3%) had malignant calcifications. The diagnostic coincidence rates of MRI, ultrasound and molybdenum target were 90.0%, 85.1% and 74.7% respectively. 258 cases of MBC received surgical treatment, including 183 cases of total mastectomy (70.9%), 53 cases of breast conserving surgery (20.5%) and 22 cases of quadrant resection (8.5%); 132 patients (51.2%) underwent axillary lymph node dissection and 93 patients (36.0%) underwent sentinel lymph node biopsy. 24 patients (9.3%) received neoadjuvant chemotherapy, of which only 2 (8.3%) achieved pathological complete remission. 56 patients (21.6%) received adjuvant radiotherapy, with a median of 25 times. 167 patients (64.5%) received adjuvant chemotherapy, and anthracycline sequential paclitaxel was the most commonly used regimen. The median follow-up was 31 months. The five-year DFS was 82.0%, and the five-year OS was 89.4%. Through Cox regression analysis, it was found that patients’ N stage (P=0.036) and receiving anthracycline sequential paclitaxel adjuvant chemotherapy (P=0.004) were independent prognostic factors. Conclusion: The histological types of MBC are complex. MRI is of high value in diagnosis. Conventional CNB is difficult to meet the needs of pathological tissue classification. Patients without lymph node metastasis and receiving anthracycline sequential paclitaxel adjuvant chemotherapy are associated with better prognosis. Through multidisciplinary standardized diagnosis and treatment, there is no significant difference between the prognosis of MBC and the common types of breast cancer. Keyword: metaplastic breast cancer; pathological characteristics; imaging; treatment; prognosis. Citation Format: Douwaner Liu, Jiajian Chen, Shuang Hao, Bingqiu Xiu, Qi Zhang, Liyi Zhang, Guangyu Liu, Zhimin Shao, Jiong Wu. A single center retrospective analysis of 259 cases of metaplastic breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P1-05-31.

Metaplastic Breast Carcinoma: A Case Series with Three Different Presentations

Metaplastic Breast Carcinoma (MBC) is one among the rare types of breast carcinoma. MBC was recognised as a separate entity by World Health Organisation (WHO) in 2020. According to WHO, metaplastic carcinoma is classified into six types based on the histology which includes: low grade adenosquamous carcinoma; fibromatosis like metaplastic carcinoma; squamous cell carcinoma; spindle cell carcinoma; carcinoma with heterologous mesenchymal differentiation; and mixed metaplastic carcinomas. This rare type of tumour shows both epithelial and/or mesenchymal elements within the same lesion. The management of these patients remains an enigma due to the rarity of the tumour and the treatment responses between patients following therapy. In the present case series, five cases of MBC and their follow-up have been described. All patients were females within the age group of 50-65 years. All five patients underwent modified radical mastectomy. Lymph node involvement was noted in one case. Among the five cases, two patients had adenosquamous carcinoma, two patients had metaplastic carcinoma with heterologous mesenchymal differentiation and one patient had mixed metaplastic carcinoma.

Tipos histológicos poco frecuentes de carcinoma infiltrante: carcinomas metaplásicos, carcinomas apocrinos y neoplasias neuroendocrinas de la mama

Metaplastic carcinomas (MCs), primary neuroendocrine cancers of the breast (NECB) and apocrine carcinomas (APCs), have undergone several changes in their definition and nomenclature over the years, and are therefore a group of special interest for discussion and updating.MCs are a heterogeneous group from a histopathological and prognostic point of view, which require appropriate sampling and a wide panel of immunohistochemical techniques to identify them. There are different subtypes with highly variable morphological characteristics and marked intra- and inter-tumoural heterogeneity. These include low-grade adenosquamous carcinoma, fibromatosis-like MC, squamous cell carcinoma, spindle cell carcinoma, MC with heterologous mesenchymal differentiation, and mixed MC. They mostly have a triple-negative immunophenotype and as a group have a poor prognosis, and poor results with the available targeted therapies.APC has a characteristic histological appearance and immunophenotype (RA+, ER-, PR-, HER2+/−, GCFP+, AMACR+), which should show predominantly in the tumor. The molecular profile or apocrine molecular signature (luminal-AR/apocrine molecular carcinoma) does not always coincide with the histopathological diagnóstico of APC. Targeted anti-androgen therapy is a therapeutic target with promising results.NE differentiation can be found in different breast tumors, either of non-special subtype, or in subtypes such as hypercellular mucinous carcinoma or solid papillary carcinoma. The diagnóstico of primary breast NEN requires morphological and immunophenotypic NE differentiation in >90% of tumor cells, first having ruled out the metastatic nature of the lesion. Two types of primary breast NEN are distinguished: NE tumor (NET) and NE carcinoma (NEC), the latter being either large cell or small cell. The prognosis and treatment of these lesions is currently like that of other infiltrating breast carcinomas according to histological grade and stage at diagnóstico.

Low-Grade Invasive Triple Negative Breast Carcinoma

Triple-negative breast carcinomas (TNBCs) are defined as estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor receptor 2-negative breast carcinomas and are composed of a heterogeneous group of breast carcinomas with most of them having aggressive behavior and poor prognosis. However, some TNBC cases are low grade with indolent clinical outcome and low risk of metastasis to other organs or regional lymph nodes. Low-grade TNBCs include low-grade adenosquamous carcinoma, fibromatosis-like metaplastic carcinoma, low-grade invasive (ductal or lobular) carcinoma with apocrine differentiation, classic adenoid cystic carcinoma, secretory carcinoma, tall cell carcinoma with reversed polarity, acinic cell carcinoma, and low-grade mucoepidermoid carcinoma. This review aims to summarize the clinicopathological correlation and the molecular features of low-grade special TNBC subtypes.

Morphological spectrum and molecular features of somatic malignant transformation in germ cell tumours.

Somatic malignant transformation (SMT) arising in germ cell tumours (GCTs) is an infrequent, but clinically relevant event. There is only limited knowledge on the morphological spectrum of SMT, and the therapeutic management of these patients is poorly defined. In this work we revisit two consecutive case series (n = 756) of GCTs. Clinicopathological data of SMTs arising in GCTs were determined, with a focus on the histopathological spectrum, and molecular aspects were obtained by Fluorescence in situ Hybridization (FISH) and Next Generation Sequencing (NGS). Thirty male patients (28 primary testicular, two primary extragonadal) were included. These patients represent 4% of GCT patients diagnosed at two institutes (University Hospital Zurich and IPO Porto). The most common SMTs were adenocarcinoma (n = 8), embryonic-type neuroectodermal tumours (ENETs, n = 8), and rhabdomyosarcoma (n = 6), but a wide range of challenging morphologies were depicted, including low-grade neuroglial tumour, adenosquamous carcinoma, neuroblastoma, and neuroendocrine carcinoma. SMT was found in 15 primary tumour samples and in 27 metastatic samples of these 30 patients, the latter showing poorer overall survival. Adenocarcinoma occurred only in metastasis postchemotherapy and in one primary retroperitoneal GCT with SMT, but not in GCT of the testis. The 12p gains were identified by FISH in all cases. NGS results were available in six patients. Clinical trials and/or targeted treatments based on the molecular profile of SMT were recommended in four patients. SMT arising in GCTs represent a diagnostic challenge and should be confirmed by a specialized uropathologist. NGS-based treatment recommendations may improve the outcome of these patients.

Abstract P1-12-03: Metaplastic carcinoma of the breast: A single-center 18-year series of 73 cases

Abstract Background: Metaplastic breast cancer (MeBC) is a rare subtype accounting for 0.2%-5% of all invasive breast cancer. They are characterized by an aggressive course and even a worse prognosis than triple-negative breast cancer (TNBC). The literature suggests that MeBCs are relatively chemoresistant; still, the patients often receive adjuvant or neoadjuvant chemotherapy during the course of treatment. This study aimed to examine the clinical management of MeBC, particularly the role of chemotherapy. Methods: This retrospective study included patients with MeBC (n=73) from the Centre des Maladies du Sein du CHU de Québec-Université Laval. The specimens were reviewed by two pathologists. Patient and tumor characteristics, systemic therapy (neoadjuvant and adjuvant), disease-free survival (DFS), and overall survival (OS) were recorded. Results: The median follow-up was 57.2 months. The mean tumor size was 39.5±32.1 (range, 1-200) mm. The vast majority had grade 3 (76.7%), no evidence of clinical nodal involvement (78.1%), and triple-negative (79.5%) disease. This population included one case (1.4%) of low-grade adenosquamous breast carcinoma, one (1.4%) of fibromatosis-like metaplastic carcinoma, 11 (15.1%) of spindle cell carcinoma, 13 (17.8%) of epidermoid carcinoma, 18 (24.7%) of MeBC with heterologous mesenchymal differentiation, and 29 (39.7%) of mixed MeBC. Chemotherapy was given to 53 (72.6%) patients. Thirty-seven patients (50.7%) had a lumpectomy, and 34/37 (91.9%) received adjuvant radiotherapy. Thirty-six patients (49.3%) had mastectomy and 22/36 (61.1%) received radiotherapy. The 5-year DFS was 55.6%, and the 5-year OS was 63.5 %. On univariable analyses, higher cT stage (cT3-4) was associated with poorer DFS and OS compared to cT1-2, respectively 13.4% vs. 70.7% (P<0.0001) and 19.9% vs. 82.8% (P<0.0001). Nodal involvement significantly influenced DFS (31.3% vs. 63.0%, P=0.011) and OS (37.5% vs. 71.6%; P=0.009). Lumpectomy was associated with a better 5-year DFS (78.4% vs. 34.0%, P<0.0001) and OS (90.6% vs. 38.8%, P<0.0001). The use of chemotherapy had a significant positive effect on 5-year DFS (64.2% vs. 31.9%, P=0.006; hazard ratio (HR)=0.45, 95% confidence interval (CI)=0.22-0.92, P=0.009) as well as 5-year OS (69.7% vs. 45.1%, P=0.035; HR=0.52, 95%CI=0.28-0.95 P=0.041). However, radiation therapy did not influence DFS (P=0.420) and OS (P=0.316). Nine patients received neoadjuvant chemotherapy; five had nodal involvement. One patient had a complete response (11.1%), five (55.6%) had a partial response, and three (33%) had progressive disease. The 5-year DFS and OS were lower for neoadjuvant chemotherapy compared with adjuvant chemotherapy (DFS: 27.8% vs. 71.5%, P=0.006; OS: 33.3% vs. 79.2%, P=0.001), but disease was more advanced in patients with neoadjuvant chemotherapy (cT3-4: 88.9% vs. 11.9%, P<0.0001). Conclusion: MeBC represents a rare heterogeneous group of malignancies with poor prognosis. Chemotherapy was associated with improved DFS and OS. Patients for neoadjuvant chemotherapy should be carefully selected. Citation Format: Kassandra J Thériault, Mariem Ben Moussa, Marjorie Perron, Christine Desbiens, Brigitte Poirier, Éric Poirier, Dominique Leblanc, Claudya Morin, Julie Lemieux, Jean-Charles Hogue, Dominique Boudreau. Metaplastic carcinoma of the breast: A single-center 18-year series of 73 cases [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-12-03.

Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis.

Simple SummaryBreast cancers that lack expression of the predictive markers oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 are known as triple-negative breast cancers (TNBCs) and are generally considered to have a poor prognosis. As available targeted treatments are not effective, aggressive chemotherapy is frequently advocated for patients with TNBC. It is now becoming apparent that TNBC is not one entity but constitutes a range of malignancies with different clinical behaviour. This paper reviews 7 distinct histological subtypes of TNBC where the overall prognosis is favourable, and aggressive systemic treatment is generally not indicated. Their recognition and separation from the larger group of no special type TNBC are important. The members of the European Working Group for Breast Screening Pathology review the morphology, known molecular features and reported outcomes, and formulate a consensus statement regarding the approach to the subtypes that are associated with a favourable prognosis.Triple-negative breast cancers (TNBC), as a group of tumours, have a worse prognosis than stage-matched non-TNBC and lack the benefits of routinely available targeted therapy. However, TNBC is a heterogeneous group of neoplasms, which includes some special type carcinomas with a relatively indolent course. This review on behalf of the European Working Group for Breast Screening Pathology reviews the literature on the special histological types of BC that are reported to have a triple negative phenotype and indolent behaviour. These include adenoid cystic carcinoma of classical type, low-grade adenosquamous carcinoma, fibromatosis-like metaplastic carcinoma, low-grade mucoepidermoid carcinoma, secretory carcinoma, acinic cell carcinoma, and tall cell carcinoma with reversed polarity. The pathological and known molecular features as well as clinical data including treatment and prognosis of these special TNBC subtypes are summarised and it is concluded that many patients with these rare TNBC pure subtypes are unlikely to benefit from systemic chemotherapy. A consensus statement of the working group relating to the multidisciplinary approach and treatment of these rare tumour types concludes the review.

Breast carcinomas of low malignant potential.

Some breast carcinomas have a very low likelihood of metastasis to regional lymph nodes and distant sites and may be considered carcinomas of low malignant potential. In this article, we review the clinical, pathologic, immunophenotypic, and molecular features of selected breast carcinomas of low malignant potential including low-grade adenosquamous carcinoma, fibromatosis-like metaplastic carcinoma, encapsulated papillary carcinoma, solid papillary carcinoma, and tall cell carcinoma with reversed polarity.

Low-grade adenosquamous carcinoma of the breast: a review with focus on imaging and management.

Low-grade adenosquamous carcinoma is a less frequent variant of metaplastic breast carcinoma, incidentally detected during screening and has an age distribution similar to other breast carcinomas. It shares characteristics with both benign and malignant carcinomas: its mammographic and sonographic features are therefore nonspecific. Breast conserving surgery with adjuvant radiation therapy is currently the preferred therapeutic approach. The aim of this review is to describe the imaging and clinical features of low-grade adenosquamous carcinoma for appropriate identification and diagnosis. The associated pitfalls, histopathologic and epidemiologic factors, natural course, and management of low-grade adenosquamous carcinoma are also discussed.

A Case of Low-grade Adenosquamous Carcinoma of the Breast

A Case of Low-grade Adenosquamous Carcinoma of the Breast

Metaplastic carcinoma of breast: A rare histological entity

Metaplastic breast carcinomas constitutes <1% of all the invasive breast carcinomas, characterized by areas of metaplasia, typically with squamous, spindle, osseous, or chondroid differentiation in the background of adenocarcinoma. We report a case of a 50 year old female who presented with a large, non tender, hard lump since 1 month diagnosed as low grade adenosquamous carcinoma on histopathological examination along with triple negativity on immunohistochemistry. The case is presented to highlight its rarity, histomorphological characteristics, undefined treatment and poor prognosis.

A novel collision tumour of myofibroblastoma and low-grade adenosquamous carcinoma in breast

BackgroundMyofibroblastoma (MFB) and low-grade adenosquamous carcinoma (LGASC) are rare tumours in the breast, respectively. However, a collision tumour of the two types has never been reported.Case presentationA 42-year-old female presented with a palpable mass in diameter of about 2.5 cm in the left breast. Morphologically, the lesion was predominately composed of bland spindle cells admixed with some islands of mature adipocytes and a few epithelial elements dispersing in infiltrating way which formed both tubule and solid structures. The mass showed low positive index of Ki-67. The spindle cells were strongly and diffusely positive for CD34, SMA, desmin, ER and PR. The epithelial elements were positive for CK and EMA, and negative for ER and PR completely. CK5/6 and P63 were positive in the outer-layer of the tubules and nearly all the cells of the solid nests.ConclusionsA collision tumour of MFB and LGASC in breast is extremely rare and either component is supposed to be not overlooked. Excision and close follow-up are advised.

Low-grade adenosquamous carcinoma of the breast.

The Breast JournalVolume 26, Issue 9 p. 1845-1846 BREAST IMAGES Low-grade adenosquamous carcinoma of the breast Laura Thornley MBChB DipPEC, Corresponding Author Laura Thornley MBChB DipPEC laurajeanthornley@gmail.com orcid.org/0000-0003-1464-2701 University of Witwatersrand, Johannesburg, South Africa Correspondence Laura Thornley, University of the Witwatersrand – Surgery, 7 York Rd Parktown Johannesburg, Johannesburg, Braamfontein Gauteng 2050, South Africa. Email: laurajeanthornley@gmail.comSearch for more papers by this authorSimon Nayler MBBCh FFPath (SA) MMed Wits, Simon Nayler MBBCh FFPath (SA) MMed Wits University of Witwatersrand, Johannesburg, South Africa Gritzman and Thatcher Inc, Johannesburg, South Africa Wits University Donald Gordan Medical Centre, Johannesburg, South AfricaSearch for more papers by this authorCarol-Ann Benn MBChB FCS (SA), Carol-Ann Benn MBChB FCS (SA) University of Witwatersrand, Johannesburg, South Africa Netcare Breast Care Centre of Excellence, Johannesburg, South AfricaSearch for more papers by this author Laura Thornley MBChB DipPEC, Corresponding Author Laura Thornley MBChB DipPEC laurajeanthornley@gmail.com orcid.org/0000-0003-1464-2701 University of Witwatersrand, Johannesburg, South Africa Correspondence Laura Thornley, University of the Witwatersrand – Surgery, 7 York Rd Parktown Johannesburg, Johannesburg, Braamfontein Gauteng 2050, South Africa. Email: laurajeanthornley@gmail.comSearch for more papers by this authorSimon Nayler MBBCh FFPath (SA) MMed Wits, Simon Nayler MBBCh FFPath (SA) MMed Wits University of Witwatersrand, Johannesburg, South Africa Gritzman and Thatcher Inc, Johannesburg, South Africa Wits University Donald Gordan Medical Centre, Johannesburg, South AfricaSearch for more papers by this authorCarol-Ann Benn MBChB FCS (SA), Carol-Ann Benn MBChB FCS (SA) University of Witwatersrand, Johannesburg, South Africa Netcare Breast Care Centre of Excellence, Johannesburg, South AfricaSearch for more papers by this author First published: 11 April 2020 https://doi.org/10.1111/tbj.13840Citations: 2Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume26, Issue9September 2020Pages 1845-1846 RelatedInformation

Low-grade variants of triple-negative breast carcinoma (TNBC): a review

Low-grade triple negative breast carcinoma (TNBC) differ from conventional type TNBC in clinical, histologic, immunophenotypic, and molecular features. Salient features of low-grade variants of TNBC including adenoid cystic carcinoma (AdCC), secretory carcinoma, low-grade adenosquamous carcinoma (LGASC) and acinic cell carcinoma (ACC), will be discussed, including those useful in distinguishing these unique entities from more commonly encountered differential diagnoses.

A Case of Low-grade Adenosquamous Carcinoma of the Breast

乳腺の低異型度腺扁平上皮癌は化生癌に分類されるが，予後は良好な疾患である．今回，右乳癌に対し温存術を行い，8年後に同側乳房に低異型度腺扁平上皮癌を発症した1例を経験したので報告する．

Low-grade Adenosquamous Carcinoma of the Breast: A Case Report

Low-grade Adenosquamous Carcinoma of the Breast: A Case Report